215 related articles for article (PubMed ID: 10721059)
1. Therapeutic potential of melatonin in immunodeficiency states, viral diseases, and cancer.
Maestroni GJ
Adv Exp Med Biol; 1999; 467():217-26. PubMed ID: 10721059
[TBL] [Abstract][Full Text] [Related]
2. MLT and the immune-hematopoietic system.
Maestroni GJ
Adv Exp Med Biol; 1999; 460():395-405. PubMed ID: 10810540
[TBL] [Abstract][Full Text] [Related]
3. The photoperiod transducer melatonin and the immune-hematopoietic system.
Maestroni GJ
J Photochem Photobiol B; 1998 Jun; 43(3):186-92. PubMed ID: 9718719
[TBL] [Abstract][Full Text] [Related]
4. Melatonin and the immune-hematopoietic system therapeutic and adverse pharmacological correlates.
Maestroni GJ; Conti A
Neuroimmunomodulation; 1996; 3(6):325-32. PubMed ID: 9266542
[TBL] [Abstract][Full Text] [Related]
5. The immunotherapeutic potential of melatonin.
Maestroni GJ
Expert Opin Investig Drugs; 2001 Mar; 10(3):467-76. PubMed ID: 11227046
[TBL] [Abstract][Full Text] [Related]
6. Immune effects of preoperative immunotherapy with high-dose subcutaneous interleukin-2 versus neuroimmunotherapy with low-dose interleukin-2 plus the neurohormone melatonin in gastrointestinal tract tumor patients.
Lissoni P; Brivio F; Brivio O; Fumagalli L; Gramazio F; Rossi M; Emanuelli G; Alderi G; Lavorato F
J Biol Regul Homeost Agents; 1995; 9(1):31-3. PubMed ID: 8553906
[TBL] [Abstract][Full Text] [Related]
7. A randomised study with subcutaneous low-dose interleukin 2 alone vs interleukin 2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melanoma.
Lissoni P; Barni S; Tancini G; Ardizzoia A; Ricci G; Aldeghi R; Brivio F; Tisi E; Rovelli F; Rescaldani R
Br J Cancer; 1994 Jan; 69(1):196-9. PubMed ID: 8286206
[TBL] [Abstract][Full Text] [Related]
8. Age-related decline in melatonin and its MT1 receptor are associated with decreased sensitivity to melatonin and enhanced mammary tumor growth.
Hill SM; Cheng C; Yuan L; Mao L; Jockers R; Dauchy B; Blask DE
Curr Aging Sci; 2013 Feb; 6(1):125-33. PubMed ID: 23895529
[TBL] [Abstract][Full Text] [Related]
9. Neuroimmunotherapy of untreatable metastatic solid tumors with subcutaneous low-dose interleukin-2, melatonin and naltrexone: modulation of interleukin-2-induced antitumor immunity by blocking the opioid system.
Lissoni P; Malugani F; Malysheva O; Kozlov V; Laudon M; Conti A; Maestroni G
Neuro Endocrinol Lett; 2002 Aug; 23(4):341-4. PubMed ID: 12195238
[TBL] [Abstract][Full Text] [Related]
10. Melatonin as biological response modifier in cancer patients.
Neri B; de Leonardis V; Gemelli MT; di Loro F; Mottola A; Ponchietti R; Raugei A; Cini G
Anticancer Res; 1998; 18(2B):1329-32. PubMed ID: 9615811
[TBL] [Abstract][Full Text] [Related]
11. A study of the mechanisms involved in the immunostimulatory action of the pineal hormone in cancer patients.
Lissoni P; Barni S; Tancini G; Rovelli F; Ardizzoia A; Conti A; Maestroni GJ
Oncology; 1993; 50(6):399-402. PubMed ID: 8233281
[TBL] [Abstract][Full Text] [Related]
12. Modulation of anticancer cytokines IL-2 and IL-12 by melatonin and the other pineal indoles 5-methoxytryptamine and 5-methoxytryptophol in the treatment of human neoplasms.
Lissoni P
Ann N Y Acad Sci; 2000; 917():560-7. PubMed ID: 11268384
[TBL] [Abstract][Full Text] [Related]
13. Biotherapy with the pineal immunomodulating hormone melatonin versus melatonin plus aloe vera in untreatable advanced solid neoplasms.
Lissoni P; Giani L; Zerbini S; Trabattoni P; Rovelli F
Nat Immun; 1998; 16(1):27-33. PubMed ID: 9789122
[TBL] [Abstract][Full Text] [Related]
14. Abrogation of the negative influence of opioids on IL-2 immunotherapy of renal cell cancer by melatonin.
Lissoni P; Mandalà M; Brivio F
Eur Urol; 2000 Jul; 38(1):115-8. PubMed ID: 10859453
[TBL] [Abstract][Full Text] [Related]
15. Anticancer neuroimmunomodulation by pineal hormones other than melatonin: preliminary phase II study of the pineal indole 5-methoxytryptophol in association with low-dose IL-2 and melatonin.
Lissoni P; Fumagalli L; Paolorossi F; Rovelli F; Roselli MG; Maestroni GJ
J Biol Regul Homeost Agents; 1997; 11(3):119-22. PubMed ID: 9498162
[TBL] [Abstract][Full Text] [Related]
16. A phase II study of neuroimmunotherapy with subcutaneous low-dose IL-2 plus the pineal hormone melatonin in untreatable advanced hematologic malignancies.
Lissoni P; Bolis S; Brivio F; Fumagalli L
Anticancer Res; 2000; 20(3B):2103-5. PubMed ID: 10928160
[TBL] [Abstract][Full Text] [Related]
17. Neuroimmunomodulation in medical oncology: application of psychoneuroimmunology with subcutaneous low-dose IL-2 and the pineal hormone melatonin in patients with untreatable metastatic solid tumors.
Lissoni P; Brivio F; Fumagalli L; Messina G; Vigoré L; Parolini D; Colciago M; Rovelli F
Anticancer Res; 2008; 28(2B):1377-81. PubMed ID: 18505083
[TBL] [Abstract][Full Text] [Related]
18. Is there a role for melatonin in supportive care?
Lissoni P
Support Care Cancer; 2002 Mar; 10(2):110-6. PubMed ID: 11862501
[TBL] [Abstract][Full Text] [Related]
19. Melatonin as a new possible anti-inflammatory agent.
Lissoni P; Rovelli F; Meregalli S; Fumagalli L; Musco F; Brivio F; Brivio O; Esposti G
J Biol Regul Homeost Agents; 1997; 11(4):157-9. PubMed ID: 9582617
[TBL] [Abstract][Full Text] [Related]
20. Effects of melatonin and melatonin receptors ligand N-[(4-methoxy-1H-indol-2-yl)methyl]propanamide on murine Colon 38 cancer growth in vitro and in vivo.
Winczyk K; Pawlikowski M; Lawnicka H; Kunert-Radek J; Spadoni G; Tarzia G; Karasek M
Neuro Endocrinol Lett; 2002 Apr; 23 Suppl 1():50-4. PubMed ID: 12019352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
